S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:ALGS

Aligos Therapeutics - ALGS Stock Forecast, Price & News

$1.10
+0.04 (+3.77%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.07
$1.12
50-Day Range
$1.00
$1.56
52-Week Range
$0.98
$17.97
Volume
34,657 shs
Average Volume
88,091 shs
Market Capitalization
$47.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Aligos Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
536.4% Upside
$7.00 Price Target
Short Interest
Healthy
1.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
0.67mentions of Aligos Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.40) to ($1.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

261st out of 1,095 stocks

Biological Products, Except Diagnostic Industry

39th out of 171 stocks

ALGS stock logo

About Aligos Therapeutics (NASDAQ:ALGS) Stock

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALGS Stock News Headlines

Where Aligos Therapeutics Stands With Analysts
Preview: Aligos Therapeutics's Earnings
See More Headlines
Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALGS Company Calendar

Last Earnings
8/04/2022
Today
10/02/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALGS
Fax
N/A
Employees
93
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+536.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-128,330,000.00
Net Margins
-1,547.22%
Pretax Margin
-1,545.16%

Debt

Sales & Book Value

Annual Sales
$4.36 million
Book Value
$4.33 per share

Miscellaneous

Free Float
36,473,000
Market Cap
$47.09 million
Optionable
Not Optionable
Beta
2.39

Key Executives

  • Dr. Lawrence M. Blatt MBA (Age 60)
    Ph.D., CEO & Chairman
    Comp: $872.58k
  • Dr. Leonid Beigelman Ph.D. (Age 63)
    Pres & Director
    Comp: $702.25k
  • Dr. Julian A. Symons DPHIL (Age 61)
    Exec. VP & Chief Scientific Officer
    Comp: $618.82k
  • Ms. Lesley Ann Calhoun CPA (Age 56)
    Exec. VP & CFO
  • Ms. Lucinda Y. Quan J.D. (Age 50)
    Exec. VP, Chief Bus. Officer & Gen. Counsel
  • Kristina Engeseth
    Exec. Director and Head of People & Culture
  • Mr. John Fry (Age 59)
    Exec. VP of Clinical Devel.
  • Dr. Matthew W. McClure M.D. (Age 50)
    Exec. VP & Chief Medical Officer
  • Dr. Sushmita M. Chanda DABT (Age 56)
    Ph.D., Exec. VP of Translational Safety Sciences
  • Dr. David B. Smith Ph.D.
    Exec. VP & Head of Chemical Operations













ALGS Stock - Frequently Asked Questions

Should I buy or sell Aligos Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aligos Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALGS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALGS, but not buy additional shares or sell existing shares.
View ALGS analyst ratings
or view top-rated stocks.

What is Aligos Therapeutics' stock price forecast for 2022?

5 analysts have issued 12-month price targets for Aligos Therapeutics' shares. Their ALGS share price forecasts range from $4.00 to $12.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 536.4% from the stock's current price.
View analysts price targets for ALGS
or view top-rated stocks among Wall Street analysts.

How have ALGS shares performed in 2022?

Aligos Therapeutics' stock was trading at $11.87 at the beginning of the year. Since then, ALGS stock has decreased by 90.7% and is now trading at $1.10.
View the best growth stocks for 2022 here
.

When is Aligos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ALGS earnings forecast
.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.18. The business had revenue of $3.69 million for the quarter. Aligos Therapeutics had a negative trailing twelve-month return on equity of 73.09% and a negative net margin of 1,547.22%. During the same quarter in the previous year, the business posted ($0.79) earnings per share.

When did Aligos Therapeutics IPO?

(ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

What is Aligos Therapeutics' stock symbol?

Aligos Therapeutics trades on the NASDAQ under the ticker symbol "ALGS."

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aligos Therapeutics' stock price today?

One share of ALGS stock can currently be purchased for approximately $1.10.

How much money does Aligos Therapeutics make?

Aligos Therapeutics (NASDAQ:ALGS) has a market capitalization of $47.09 million and generates $4.36 million in revenue each year. The company earns $-128,330,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

How can I contact Aligos Therapeutics?

The official website for the company is www.aligos.com. The company can be reached via phone at 800-466-6059 or via email at cdavis@lifesciadvisors.com.

This page (NASDAQ:ALGS) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.